Regulatory
Catalyst Pharmaceuticals, Inc. announced that it will release second quarter 2019 financial result after market close on Wednesday, August 7, 2019.
Daiichi Sankyo Europe GmbH announced that results from the 12-week, pivotal Phase 3 bempedoic acid / ezetimibe FDC tablet study (also known as Study 053) were published in the European Journal of Preventative Cardiology.
As reported yesterday, the Trump administration is evaluating proposals to allow consumers to buy drugs legally from Canada. Today, their efforts became more official as the U.S. Department of Health and Human Services announced their intentions.
Esperion announced it will report second quarter 2019 financial results on August 8, 2019 before the U.S. financial markets open.
Company Offers Novel Ebola Vaccine for Public Health use...Gratis
TLC announced financial results for the second quarter ended June 30, 2019, and provided a business update.
Hutchison China MediTech Limited announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs.
On July 18, it was reported by Reuters that Canada is opposed to any U.S. plans to buy Canadian prescription drugs because the country fears it will threaten its own drug supply or raise costs for its own people.
There were two issues the agency had. First, the FDA wanted the inclusion of two animal studies to evaluate whether the drug caused thickening of the heart valve. The second was more of a goof—the contract research organization Zogenix employed uploaded the wrong data set for the application.
MorphoSys AG will publish its first six months’ 2019 results on August 6, 2019 at 10:00pm CEST.
PRESS RELEASES